Key result
Emerging antiplatelet agents target novel pathways to decouple thrombosis from hemostasis and reduce bleeding.
This review evaluates evolving strategies to optimize established antiplatelet agents, emerging agents for prehospital acute myocardial infarction and CYP2C19-independent clopidogrel alternatives, and novel molecular targets aimed at decoupling thrombosis from hemostasis.
Emerging antiplatelet agents may address bleeding and variability limits; leaves open their adoption pending rigorous trials.
Current antiplatelet therapies reduce thrombotic, particularly atherothrombotic events but remain constrained by bleeding risk, residual ischemic events, and pharmacokinetic or pharmacogenomic limitations. This review first evaluates the evolving strategies to optimize established agents, including P2Y12 monotherapy, genotype-guided de-escalation, aspirin formulation research, and aspirin in cancer chemoprevention. Second, it examines emerging agents designed for prehospital use in acute myocardial infarction and CYP2C19-independent clopidogrel alternatives aimed at improving global access. Finally, novel molecular targets including glycoprotein VI, protease-activated receptor 4, 12-lipoxygenase, and glycoprotein Ibα that aim to decouple thrombosis from hemostasis are discussed.
No takes yet. Share an insight, caveat, or question.
Ahmed et al. (2026) conducted a review in Atherothrombotic events and acute myocardial infarction. Emerging antiplatelet agents and optimization strategies was evaluated. Emerging antiplatelet agents and strategies target P2Y12, GPVI, PAR4, 12-LOX, and GPIbα to decouple thrombosis from hemostasis and overcome bleeding risks.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: